Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
nahHQKDt2nhSFFu5
Listen
